{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(3)"],"submitter":["Dedong C"],"pubmed_abstract":["<h4>Objective</h4>To evaluate the effect of ShenQi FuZheng Injection (SFI) on cellular immunity and clinical efficacy in patients with advanced non small cell lung cancer(NSCLC) when combined with chemotherapy.<h4>Methods</h4>Electronic databases including EMBASE, PUBMED, the conference proceedings of the American Society of Clinical Oncology (ASCO), Cochrane, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biological Medical disc(CBM) were searched, until July, 2015. The randomized controlled clinical studies reporting results of efficacy and immune function were collected according to the inclusion criteria. Cochrane handbook 5.1.0 was applied to assess the quality of included trials and Revman 5 software was used for data analysis.<h4>Results</h4>Fifteen studies including "],"journal":["PloS one"],"pagination":["e0152270"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4807845"],"repository":["biostudies-literature"],"pubmed_title":["The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis."],"pmcid":["PMC4807845"],"pubmed_authors":["Huilin X","Dedong C","Anbing H","Wei G","Ximing X"],"additional_accession":[]},"is_claimable":false,"name":"The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.","description":"<h4>Objective</h4>To evaluate the effect of ShenQi FuZheng Injection (SFI) on cellular immunity and clinical efficacy in patients with advanced non small cell lung cancer(NSCLC) when combined with chemotherapy.<h4>Methods</h4>Electronic databases including EMBASE, PUBMED, the conference proceedings of the American Society of Clinical Oncology (ASCO), Cochrane, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biological Medical disc(CBM) were searched, until July, 2015. The randomized controlled clinical studies reporting results of efficacy and immune function were collected according to the inclusion criteria. Cochrane handbook 5.1.0 was applied to assess the quality of included trials and Revman 5 software was used for data analysis.<h4>Results</h4>Fifteen studies including ","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016","modification":"2025-04-19T01:25:40.172Z","creation":"2019-03-26T22:53:42Z"},"accession":"S-EPMC4807845","cross_references":{"pubmed":["27015629"],"doi":["10.1371/journal.pone.0152270"]}}